All the while the company's done a good job of maintaining strong gross margins in a tough reimbursement market like the U.S.. That means they're controlling costs well on the manufacturing side, which isn't an easy thing to do.
Early on, treating (sleep apnea) was largely a lifestyle issue because people were falling asleep in the day and this would help them feel better.
Getting European Commission approval is a key step ... but the fact that there has been such a disconnect between the takeout price of $76 (per Guidant share) and the current share price tells you there's more uncertainty and nervousness out there than normal.
I think the company in general is in very good shape, but there are some general investor concerns about how long Stryker can maintain its 20-plus percent growth in earnings operational rate.
If you don't invest in R&D, you're going to get left behind, because all the other companies are doing it.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.